Shopping Cart 0
Cart Subtotal
USD 0

Colorectal Cancer - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Colorectal Cancer-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer-Pipeline Review, H2 2018, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.

Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 28, 157, 178, 17, 204, 39 and 13 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 23, 9, 1, 35 and 5 molecules, respectively.

Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).

- The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 13

Colorectal Cancer-Overview 14

Colorectal Cancer-Therapeutics Development 15

Colorectal Cancer-Therapeutics Assessment 83

Colorectal Cancer-Companies Involved in Therapeutics Development 115

Colorectal Cancer-Drug Profiles 257

Colorectal Cancer-Dormant Projects 2439

Colorectal Cancer-Discontinued Products 2462

Colorectal Cancer-Product Development Milestones 2468

Appendix 2479


List Of Figure

List of Figures

Number of Products under Development for Colorectal Cancer, H2 2018 83

Number of Products under Development by Companies, H2 2018 84

Number of Products under Development by Universities/Institutes, H2 2018 106

Number of Products by Top 10 Targets, H2 2018 151

Number of Products by Stage and Top 10 Targets, H2 2018 151

Number of Products by Top 10 Mechanism of Actions, H2 2018 165

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 165

Number of Products by Top 10 Routes of Administration, H2 2018 179

Number of Products by Stage and Top 10 Routes of Administration, H2 2018 179

Number of Products by Top 10 Molecule Types, H2 2018 181

Number of Products by Stage and Top 10 Molecule Types, H2 2018 181


List Of Table

List of Tables

Number of Products under Development for Colorectal Cancer, H2 2018 83

Number of Products under Development by Companies, H2 2018 85

Number of Products under Development by Universities/Institutes, H2 2018 106

Products under Development by Companies, H2 2018 110

Products under Development by Universities/Institutes, H2 2018 146

Number of Products by Stage and Target, H2 2018 152

Number of Products by Stage and Mechanism of Action, H2 2018 166

Number of Products by Stage and Route of Administration, H2 2018 180

Number of Products by Stage and Molecule Type, H2 2018 182

Colorectal Cancer-Pipeline by 3-V Biosciences Inc, H2 2018 183

Colorectal Cancer-Pipeline by 3SBio Inc, H2 2018 183

Colorectal Cancer-Pipeline by 4SC AG, H2 2018 184

Colorectal Cancer-Pipeline by Aadi Bioscience Inc, H2 2018 184

Colorectal Cancer-Pipeline by AB Science SA, H2 2018 185

Colorectal Cancer-Pipeline by AbbVie Inc, H2 2018 185

Colorectal Cancer-Pipeline by AbGenomics International Inc, H2 2018 186

Colorectal Cancer-Pipeline by Abpro, H2 2018 186

Colorectal Cancer-Pipeline by Aclaris Therapeutics Inc, H2 2018 186

Colorectal Cancer-Pipeline by Adamed Sp z oo, H2 2018 187

Colorectal Cancer-Pipeline by ADC Therapeutics SA, H2 2018 187

Colorectal Cancer-Pipeline by Adhera Therapeutics, H2 2018 188

Colorectal Cancer-Pipeline by Aduro BioTech Inc, H2 2018 188

Colorectal Cancer-Pipeline by Advanced Accelerator Applications SA, H2 2018 189

Colorectal Cancer-Pipeline by Advanced BioDesign, H2 2018 189

Colorectal Cancer-Pipeline by Advenchen Laboratories LLC, H2 2018 189

Colorectal Cancer-Pipeline by Agency for Science, Technology and Research, H2 2018 190

Colorectal Cancer-Pipeline by Agenus Inc, H2 2018 190

Colorectal Cancer-Pipeline by AlfaSigma SpA, H2 2018 191

Colorectal Cancer-Pipeline by Alkermes Plc, H2 2018 191

Colorectal Cancer-Pipeline by Alligator Bioscience AB, H2 2018 192

Colorectal Cancer-Pipeline by Allinky Biopharma SL, H2 2018 192

Colorectal Cancer-Pipeline by Almac Discovery Ltd, H2 2018 192

Colorectal Cancer-Pipeline by Alpine Immune Sciences Inc, H2 2018 193

Colorectal Cancer-Pipeline by ALX Oncology Inc, H2 2018 193

Colorectal Cancer-Pipeline by Amarin Corp Plc, H2 2018 194

Colorectal Cancer-Pipeline by amcure GmbH, H2 2018 194

Colorectal Cancer-Pipeline by Amgen Inc, H2 2018 195

Colorectal Cancer-Pipeline by APEIRON Biologics AG, H2 2018 195

Colorectal Cancer-Pipeline by Apexigen Inc, H2 2018 195

Colorectal Cancer-Pipeline by Aphios Corp, H2 2018 196

Colorectal Cancer-Pipeline by Apogenix AG, H2 2018 196

Colorectal Cancer-Pipeline by Aposense Ltd, H2 2018 197

Colorectal Cancer-Pipeline by Arcus Biosciences Inc, H2 2018 197

Colorectal Cancer-Pipeline by Array BioPharma Inc, H2 2018 198

Colorectal Cancer-Pipeline by Arvinas Inc, H2 2018 198

Colorectal Cancer-Pipeline by Asana BioSciences LLC, H2 2018 199

Colorectal Cancer-Pipeline by Ascelia Pharma AB, H2 2018 199

Colorectal Cancer-Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2018 199

Colorectal Cancer-Pipeline by Astellas Pharma Inc, H2 2018 200

Colorectal Cancer-Pipeline by Astex Pharmaceuticals Inc, H2 2018 200

Colorectal Cancer-Pipeline by AstraZeneca Plc, H2 2018 201

Colorectal Cancer-Pipeline by Aurigene Discovery Technologies Ltd, H2 2018 202

Colorectal Cancer-Pipeline by Aurobindo Pharma Ltd, H2 2018 202

Colorectal Cancer-Pipeline by B Cell Design SAS, H2 2018 203

Colorectal Cancer-Pipeline by Basilea Pharmaceutica Ltd, H2 2018 203

Colorectal Cancer-Pipeline by Batu Biologics Inc, H2 2018 203

Colorectal Cancer-Pipeline by Bavarian Nordic A/S, H2 2018 204

Colorectal Cancer-Pipeline by Bayer AG, H2 2018 205

Colorectal Cancer-Pipeline by BeiGene Ltd, H2 2018 205

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

3SBio Inc

3-V Biosciences Inc

4SC AG

Aadi Bioscience Inc

AB Science SA

AbbVie Inc

AbGenomics International Inc

Abpro

Aclaris Therapeutics Inc

Adamed Sp z oo

ADC Therapeutics SA

Adhera Therapeutics

Aduro BioTech Inc

Advanced Accelerator Applications SA

Advanced BioDesign

Advenchen Laboratories LLC

Agency for Science, Technology and Research

Agenus Inc

AlfaSigma SpA

Alkermes Plc

Alligator Bioscience AB

Allinky Biopharma SL

Almac Discovery Ltd

Alpine Immune Sciences Inc

ALX Oncology Inc

Amarin Corp Plc

amcure GmbH

Amgen Inc

APEIRON Biologics AG

Apexigen Inc

Aphios Corp

Apogenix AG

Aposense Ltd

Arcus Biosciences Inc

Array BioPharma Inc

Arvinas Inc

Asana BioSciences LLC

Ascelia Pharma AB

Aslan Pharmaceuticals Pte Ltd

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Aurobindo Pharma Ltd

B Cell Design SAS

Basilea Pharmaceutica Ltd

Batu Biologics Inc

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Beijing Hanmi Pharmaceutical Co Ltd

BeyondSpring Inc

Biocon Ltd

BioLineRx Ltd

Bionomics Ltd

Bionovis SA

Biosceptre International Ltd

BioXpress Therapeutics SA

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Calithera Biosciences Inc

CanBas Co Ltd

Cancer Prevention Pharmaceuticals Inc

Canget BioTekpharma LLC

Cantargia AB

Carna Biosciences Inc

CaroGen Corp

CBT Pharmaceuticals Inc

CCRP Therapeutics GmbH

Celgene Corp

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Celleron Therapeutics Ltd

Cellestia Biotech AG

Cellix Bio Pvt Ltd

Celltrion Inc

Celyad SA

Checkmate Pharmaceuticals Inc

Chengdu Kanghong Pharmaceuticals Group Co

Chiome Bioscience Inc

Chipscreen Biosciences Ltd

ChoDang Pharm Co Ltd

Chong Kun Dang Pharmaceutical Corp

Chugai Pharmaceutical Co Ltd

Cinnagen Co

Cleveland BioLabs Inc

COARE Biotechnology Inc

Compugen Ltd

Conatus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Cotinga Pharmaceuticals Inc

Cytlimic Inc

Daiichi Sankyo Co Ltd

Deciphera Pharmaceuticals LLC

Dr. Reddy's Laboratories Ltd

eFFECTOR Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

Endor Technologies SL

Enochian Biosciences Inc

EntreChem SL

Enzene Biosciences Ltd

Enzo Biochem Inc

EpiThany Inc

Etubics Corp

Evelo Biosciences Inc

Exelixis Inc

Exicure Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Fate Therapeutics Inc

FLX Bio Inc

Fog Pharmaceuticals Inc

Forbius

Formosa Laboratories Inc

Forty Seven Inc

Fresenius SE & Co KGaA

F-star Biotechnology Ltd

Fujifilm Holdings Corporation

Fusion Antibodies plc